{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:49:01Z","timestamp":1759481341824},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s10067-018-4266-0","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T01:05:16Z","timestamp":1535072716000},"page":"3043-3050","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term effects of immunosuppressive therapy on lung function in scleroderma patients"],"prefix":"10.1007","volume":"37","author":[{"given":"Slavica","family":"Pavlov-Dolijanovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Vujasinovic Stupar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Zugic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Predrag","family":"Ostojic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Zekovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Zivanovic Radnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Jeremic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Tadic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,24]]},"reference":[{"key":"4266_CR1","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.1780370903","volume":"37","author":"VD Steen","year":"1994","unstructured":"Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283\u20131289","journal-title":"Arthritis Rheum"},{"key":"4266_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0889-857X(03)00025-5","volume":"29","author":"B White","year":"2003","unstructured":"White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin N Am 29:371\u2013390","journal-title":"Rheum Dis Clin N Am"},{"key":"4266_CR3","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962\u20133970","journal-title":"Arthritis Rheum"},{"key":"4266_CR4","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"4266_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1183\/09059180.00001813","volume":"22","author":"S Cappelli","year":"2013","unstructured":"Cappelli S, Guiducci S, Bellando Randone S, Matucci Cerinic M (2013) Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev 22:236\u2013243","journal-title":"Eur Respir Rev"},{"key":"4266_CR6","first-page":"646","volume":"16","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 16:646\u2013664","journal-title":"Am J Respir Crit Care Med"},{"key":"4266_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cpt1977213247","volume":"21","author":"FE Karch","year":"1977","unstructured":"Karch FE, Lassagna L (1977) Towards the operational identification of adverse drug reactions. Clin Pharmacol Ther 21:247\u2013254","journal-title":"Clin Pharmacol Ther"},{"key":"4266_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"4266_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/1874306400802010039","volume":"2","author":"CP Sime\u00f3n-Aznar","year":"2008","unstructured":"Sime\u00f3n-Aznar CP, Fonollosa-Pl\u00e1 V, Tolosa-Vilella C, Selva-O\u2019 Callaghan A, Solans-Laqu\u00e9 R, Palliza E et al (2008) Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2:39\u201345","journal-title":"Open Respir Med J"},{"key":"4266_CR10","first-page":"1064","volume":"35","author":"A Be\u2019rezne\u2019","year":"2008","unstructured":"Be\u2019rezne\u2019 A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D et al (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35:1064\u20131072","journal-title":"J Rheumatol"},{"key":"4266_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.semarthrit.2014.09.003","volume":"44","author":"M Iudici","year":"2015","unstructured":"Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G (2015) Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum 44:437\u2013444","journal-title":"Semin Arthritis Rheum"},{"key":"4266_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10067-005-0173-2","volume":"25","author":"P Ostojic","year":"2006","unstructured":"Ostojic P, Damjanov N (2006) Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy. Clin Rheumatol 25:819\u2013821","journal-title":"Clin Rheumatol"},{"key":"4266_CR13","first-page":"293","volume":"25","author":"P Air\u00f2","year":"2007","unstructured":"Air\u00f2 P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi M, Grottolo A, Franceschini F, Zambruni A (2007) Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25:293\u2013296","journal-title":"Clin Exp Rheumatol"},{"key":"4266_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00296-006-0217-1","volume":"27","author":"G Yiannopoulos","year":"2007","unstructured":"Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN, Andonopoulos AP (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27:357\u2013361","journal-title":"Rheumatol Int"},{"key":"4266_CR15","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00296-011-1967-y","volume":"32","author":"H Poormoghim","year":"2012","unstructured":"Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N (2012) Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int 32:2431\u20132444","journal-title":"Rheumatol Int"},{"key":"4266_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","volume":"76","author":"DP Tashkin","year":"2007","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 76:1026\u20131034","journal-title":"Am J Respir Crit Care Med"},{"key":"4266_CR17","first-page":"RA187","volume":"16","author":"K Broad","year":"2010","unstructured":"Broad K, Pope JE (2010) The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit 16:RA187\u2013RA190","journal-title":"Med Sci Monit"},{"key":"4266_CR18","doi-asserted-by":"publisher","first-page":"R124","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10:R124","journal-title":"Arthritis Res Ther"},{"key":"4266_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12079-012-0172-4","volume":"6","author":"M Hudson","year":"2012","unstructured":"Hudson M, Steele R, Canadian Scleroderma Research Group, Baron M (2012) Immunosuppression for interstitial lung disease in systemic sclerosis - novel insights and opportunities for translational research. J Cell Commun Signal 6:187\u2013190","journal-title":"J Cell Commun Signal"},{"key":"4266_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00296-014-3026-y","volume":"34","author":"H Poormoghim","year":"2014","unstructured":"Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S, Andalib E (2014) Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study. Rheumatol Int 34:1691\u20131699","journal-title":"Rheumatol Int"},{"key":"4266_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","volume":"25","author":"O Nadashkevich","year":"2006","unstructured":"Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25:205\u2013212","journal-title":"Clin Rheumatol"},{"key":"4266_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00005382-200310000-00004","volume":"18","author":"H Arakawa","year":"2003","unstructured":"Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y (2003) Methotrexate induced pulmonary injury: serial CT findings. J Thorac Imaging 18:231\u2013236","journal-title":"J Thorac Imaging"},{"key":"4266_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","volume":"191","author":"ST Panopoulos","year":"2013","unstructured":"Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP (2013) Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 191:483\u2013489","journal-title":"Lung"},{"key":"4266_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","volume":"20","author":"S Adler","year":"2018","unstructured":"Adler S, Huscher D, Siegert E, Allanore Y, Czirj\u00e1k L, DelGaldo F et al (2018) Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther 20:17","journal-title":"Arthritis Res Ther"},{"key":"4266_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/rheumatology\/keu296","volume":"54","author":"C Bruni","year":"2015","unstructured":"Bruni C, Guiducci S, Bellando-Randone S, Lepri G, Braschi F, Fiori G, Bartoli F, Peruzzi F, Blagojevic J, Matucci-Cerinic M (2015) Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology (Oxford) 54:72\u201376","journal-title":"Rheumatology (Oxford)"},{"key":"4266_CR26","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar4236","volume":"15","author":"G Valentini","year":"2013","unstructured":"Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F, Santoriello C, Ciani A, Cozzolino D, de Matteis GM, Cappabianca S, Vitelli F, Span\u00f2 A (2013) Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 15:R63","journal-title":"Arthritis Res Ther"},{"key":"4266_CR27","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s10067-015-2902-5","volume":"34","author":"LI Sakkas","year":"2015","unstructured":"Sakkas LI, Simopoulou T, Katsiari C, Bogdanos D, Chikanza IC (2015) Early systemic sclerosis-opportunities for treatment. Clin Rheumatol 34:1327\u20131331","journal-title":"Clin Rheumatol"},{"key":"4266_CR28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10067-008-0837-9","volume":"27","author":"M Ciurzy\u0144ski","year":"2008","unstructured":"Ciurzy\u0144ski M, Bienias P, Lichodziejewska B, Kurnicka K, Szewczyk A, Gli\u0144ska-Wielochowska M, Kurzyna M, B\u0142aszczyk M, Liszewska-Pfejfer D, Pruszczyk P (2008) Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 27:991\u2013997","journal-title":"Clin Rheumatol"},{"key":"4266_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.23187","volume":"58","author":"Y Allanore","year":"2008","unstructured":"Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, Mouthon L, Guillevin L, Meyer O, Ekindjian OG, Weber S, Kahan A (2008) High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58:284\u2013291","journal-title":"Arthritis Rheum"},{"key":"4266_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10067-007-0724-9","volume":"27","author":"HJ Choi","year":"2008","unstructured":"Choi HJ, Shin YK, Lee HJ, Kee JY, Shin DW, Lee EY, Lee YJ, Lee EB, Song YW (2008) The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 27:437\u2013442","journal-title":"Clin Rheumatol"},{"key":"4266_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s10067-010-1494-3","volume":"29","author":"T Dimitroulas","year":"2010","unstructured":"Dimitroulas T, Giannakoulas G, Papadopoulou K, Sfetsios T, Karvounis H, Dimitroula H, Parcharidou D, Koliakos G, Garyfallos A, Styliadis I, Settas L (2010) Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol 29:957\u2013964","journal-title":"Clin Rheumatol"},{"key":"4266_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","volume":"74","author":"B Maurer","year":"2015","unstructured":"Maurer B, Graf N, Michel BA, M\u00fcller-Ladner U, Czirj\u00e1k L, Denton CP, Tyndall A, Metzig C, Lanius V, Khanna D, Distler O, EUSTAR co-authors (2015) Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 74:1124\u20131131","journal-title":"Ann Rheum Dis"},{"key":"4266_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11926-013-0326-2","volume":"15","author":"K Naraghi","year":"2013","unstructured":"Naraghi K, van Laar JM (2013) Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep 15:326\u2013331","journal-title":"Curr Rheumatol Rep"},{"key":"4266_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/bmt.2016.211","volume":"52","author":"N Papa Del","year":"2017","unstructured":"Del Papa N, Onida F, Zaccara E, Saporiti G, Maglione W, Tagliaferri E et al (2017) Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 52:53\u201358","journal-title":"Bone Marrow Transplant"},{"key":"4266_CR35","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Laar van","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht A, Daikeler T, K\u00f6tter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Qu\u00e9r\u00e9 I, Rich \u00c9, Westhovens R, Griffiths B, Saccardi R, van den Hoogen F, Fibbe WE, Soci\u00e9 G, Gratwohl A, Tyndall A, EBMT\/EULAR Scleroderma Study Group (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311:2490\u20132498","journal-title":"JAMA"},{"key":"4266_CR36","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10067-017-3954-5","volume":"37","author":"G Helbig","year":"2018","unstructured":"Helbig G, Widuchowska M, Kocl\u0119ga A, Kopi\u0144ska A, Kope\u0107-M\u0119drek M, Gawe\u0142 WB, Spa\u0142ek A, \u017bak J, Grygoruk-Wi\u015bniowska I, Liwoch R, Kucharz E, Markiewicz M (2018) Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis. Clin Rheumatol 37:1709\u20131714","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4266-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T19:13:34Z","timestamp":1566587614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,24]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4266"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4266-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,24]]},"assertion":[{"value":"11 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}